Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Intracerebral Hemorrhage
• Age: Between 50 years - 150 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Spontaneous lobar Intracerebral hemorrhage (ICH) within 7 days prior to randomization confirmed by CT or MRI scan
  2. Participants was taking a statin drug at the onset of the qualifying/index Intracerebral hemorrhage (ICH)
  3. Randomization must be carried out within 7 days of the onset of the qualifying Intracerebral hemorrhage (ICH)
  4. Participant or legally authorized representative, after consultation with physicians, agrees to be randomized to statin continuation (restart) vs. discontinuation

  
  

You may not be eligible for this study if the following are true:

• 1. Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct
  2. History of recent myocardial infarction or unstable angina within the previous 3 months
  3. Diabetic patients with history of myocardial infarction or coronary revascularization
  4. History of familial hypercholesterolemia
  5. Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors
  6. Known diagnosis of severe dementia
  7. Inability to obtain informed consent
  8. Patient known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits/assessments.
  9. Life expectancy of less than 24 months due to co-morbid terminal conditions.
  10. Contraindications to continuation/resumption of statin therapy, such as significant elevations of serum creatinine kinase and/or liver transaminases, and rhabdomyolysis
  11. Women of childbearing potential, defined as pre-menopausal women capable of becoming pregnant
  12. Concurrent participation in another research protocol for investigation of experimental therapy.
  13. Indication that withdrawal of care will be implemented for the qualifying ICH.